In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $8.30.
According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 6.1% and a 38.6% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology.
Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.00, implying a 92.8% upside from current levels. In a report issued on December 7, RBC Capital also maintained a Buy rating on the stock with a $11.00 price target.
Based on BELLUS Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4,000 and GAAP net loss of $22.88 million. In comparison, last year the company earned revenue of $3,000 and had a GAAP net loss of $5.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Read More on BLU:
- Analysts Are Bullish on Top Consumer Goods Stocks: Nike (NKE), Coty (COTY)
- Jefferies Maintains Their Buy Rating on Olema Pharmaceuticals (OLMA)
- UBS Found Guilty in French Tax Case; Penalty Slashed to $2B
- Analysts Are Bullish on Top Technology Stocks: Boeing (BA), TE Connectivity (TEL)
- RH Updates 1 Key Risk Factor